Peerview Clinical Pharmacology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/VMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence. Upon completion of this activity, participants should be better able to: Assess the severity of asthma in pediatric and adult patients according to evidence-based practice guidelines, Identify patients that would likely benefit from targeted therapy, considering the relationship between type 2 inflammation, moderate to severe asthma, and comorbid conditions such as atopic dermatitis, Select treatment for pediatric and adult patients with uncontrolled, moderate to severe asthma according to current evidence and guidelines, Use techniques to educate and communicate more effectively with patients and caregivers to better engage them in their care, and improve adherence

Go online to PeerView.com/GPD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in nephrology discusses the prevention and management of nephropathy in patients with Fabry disease. Upon completion of this activity, participants should be better able to: Employ evidence-based tools and strategies to identify patients with FD and prevent nephropathy in a timely manner, Assess safety and efficacy of current and emerging treatments for patients with FD, Apply individualized treatment for patients with FD with an emphasis on preventing nephropathy.

Go online to PeerView.com/KZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have favorable, dose-dependent effects on both glycemia and weight, but dual incretin agonists may permit more intensive glycemic targets with greater weight loss. In this engaging PeerView Late Night activity, based on a recent live web broadcast, host Dr. Javier Morales is joined by special guests Drs. Juan Pablo Frías and Donna H. Ryan. Together, they discuss the interrelationship between type 2 diabetes mellitus (T2DM) and obesity, while exploring the potential role of combining glucose-dependent insulinotropic polypeptide (GIP) with GLP-1 RAs as dual incretin agonist therapy. GIP/GLP-1 RAs are evaluated in terms of their ability to personalize treatment for patients with T2DM and obesity, specifically for controlling glycemia and weight and avoiding long-term complications. Upon completion of this activity, participants

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent scientific developments with multicancer early detection tests? Find out more in this activity, which features a multidisciplinary panel’s take on the potential of blood-based cancer screening, the implications of emerging MCED blood tests for primary care practice, and collaborative, case-based strategies for incorporating these innovations into routine patient care. Upon completion of this activity, participants should be better able to: Assess the scientific foundations and clinical utility of novel multicancer early detection (MCED) tests, including available clinical evidence on sensitivity, specificity, and tumor localization accuracy, Plan strategies to appropriately integrate MCED tests into routine primary care practice based on

Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tumor treating fields (TTFields)? If you are like many oncologists, gynecologists, and other clinicians involved in the treatment of patients with ovarian cancer, you may be struggling to understand which patients will benefit from treatment with these newer approaches. Join PeerView for an educational activity designed to provide busy healthcare practitioners with the information they need to use these treatments in clinical practice. Our expert faculty will provide an in-depth look at recent clinical evidence and ongoing research on PARP inhibitors, TTFields, and other novel strategies in ovarian cancer and practical guidance, drawn from their own experience, on incorporating new treatments, including through clinical trial enrollment

Go online to PeerView.com/GVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Successfully and safely delivering optimized care in metastatic colorectal cancer (mCRC) can be a challenge, particularly during later lines of therapy and when managing patients exposed to many prior therapies. Current evidence shows that these challenges can be overcome—including through the optimized delivery of novel agents, enhanced dosing strategies, and AE mitigation approaches. To learn more, join CRC expert, Dr. Tanios Bekaii-Saab, as he navigates through different team-based treatment strategies designed to improve the delivery of later-line care in patients with mCRC. Upon completion of this activity, participants should be better able to: Summarize recent evidence regarding dosage optimization of third-line treatments for metastatic colorectal cancer (mCRC), Implement alternative dose strategies based on the latest data to maximize third-line therapeutic efficacy in

Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates (ADCs) are showing great promise in improving outcomes in patients who currently have limited options. How should patients who would benefit from these novel ADCs be identified, and does biomarker testing have a role? Where do the HER2-, HER3-, and TROP2-targeting therapies fit within the current treatment arsenal for advanced/metastatic NSCLC, and what is the best way to integrate them into practice? These and other questions are addressed by top experts in this PeerView MasterClass and Practicum. Faculty navigate through the evidence base, provide practical guidance regarding the clinical role and integration of novel ADCs, and discuss illustrative cases to help you better understand how to t

Go online to PeerView.com/AFZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psychiatry discuss recent advances in the management of patients with major depressive disorder and postpartum depression. Upon completion of this activity, participants should be better able to: Recognize the burden of major depressive disorder and postpartum depression and the impact of delayed or suboptimal treatment on patient outcomes, Describe the role of GABAergic dysregulation in the pathophysiology of depression and the rationale for GABA-A receptor modulation with neuroactive steroids, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for major depressive disorder and postpartum depression, recognizing potential implications for the future treatment landscape, Implement evidence-based, individualized treatment plans for patients with major depressive disorder and postpartum depression.

Go online to PeerView.com/HYR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in women’s behavioral health shares a downloadable tool kit created for OB/GYNs and other clinicians to facilitate the screening, diagnosis, and treatment of postpartum depression (PPD) and to provide guidance on the use of shared decision-making strategies to optimize patient care. Upon completion of this activity, participants should be better able to: Utilize validated screening tools and current clinical guidelines to facilitate the early diagnosis of PPD, Evaluate the mechanisms of action, efficacy, safety, and tolerability of current and emerging treatments for PPD, Develop individualized treatment protocols for patients with PPD that incorporate evidence-based care and shared decision-making.

Go online to PeerView.com/YSX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence. Upon completion of this activity, participants should be better able to: Determine the presence of tumor lysis syndrome (TLS) and risk status based on patient-, disease-, and treatment-related features in

Go online to PeerView.com/DQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in acute hepatic porphyria (AHP) reviews the diagnostic criteria for AHP and examines current treatment options. Upon completion of this activity, participants should be better able to: Apply laboratory and diagnostic assessments to confirm suspicion of AHP, Recognize disease burdens that patients with AHP frequently experience (eg, impact on overall health, quality of life, daily activities), Employ evidence-based treatment regimens that include siRNA therapy, as appropriate, to improve outcomes, minimize disease impact, and reduce the burdens of disease in patients with AHP.

Go online to PeerView.com/TRX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to bring the new standard of care for advanced renal cell carcinoma (RCC) into your clinical practice? Join PeerView and KCCure to learn what the latest research on multi-targeted TKIs, immune checkpoint inhibitors, and combination strategies (dual checkpoint blockade and immune checkpoint inhibitor/TKI combinations) means for your patients with advanced disease. Our panel of experts will discuss how highly efficacious therapeutic strategies are changing outcomes in earlier lines of treatment and the potential for approved agents to be used in new settings. With illustrative patient cases guiding the discussion, this engaging activity will provide participants with the information they need to navigate important clinical decisions, including how to sequence available therapies; which systemic therapies to use in patients with metastatic, locally advanced, or high-r

Go online to PeerView.com/TFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in the management of venous thromboembolism (VTE) discuss the importance of a timely diagnosis, appropriate treatment selection, and extended anticoagulation therapy for secondary prevention. Upon completion of this activity, participants should be better able to: Apply appropriate evidence-based clinical decision tools in an interprofessional manner to identify patients in primary care at risk for VTE, Compare the efficacy and safety profile and dosing regimens of available treatment options for VTE, Implement the most up-to-date evidence-based guidelines in the management of VTE to determine an individually appropriate treatment strategy for each patient, Explain the indications and rationale for standard vs extended treatment for the secondary prevention of VTE, Educate patients on the heightened risk of VTE recurrence, and the importance of trea

Go online to PeerView.com/FFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a neurologist discusses the life-changing impact of gene replacement therapy in spinal muscular atrophy. Upon completion of this CE activity, participants will be able to: Recognize the underlying genetics and pathophysiology of spinal muscular atrophy, Identify appropriate patients with SMA for treatment with gene replacement therapy, Counsel patients, families, and caregivers about gene replacement therapy for SMA, including eligibility, potential benefits and risks, and anticipatory guidance regarding prognosis, the need for ongoing care, and long-term safety monitoring, Employ post-treatment multidisciplinary management plans for patients who have been treated for SMA with gene replacement therapy.

Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to include expanded and detailed recommendations for the use of dual antiplatelet therapy (DAPT), the combination of aspirin and clopidogrel or ticagrelor, to further reduce the risk of stroke. These guidelines also include specific recommendations for individuals with minor acute ischemic stroke (AIS) or a TIA. In this activity based on a recent s

Go online to PeerView.com/JCU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in complement 3 glomerulopathy (C3G) discusses evidence-based approaches to differentially diagnose patients with C3G and reviews the evidence for current and emerging treatment strategies. Upon completion of this activity, participants should be better able to: Explain the pathophysiology of C3G, highlighting the rationale for using complement proteins and proteinuria as therapeutic targets, Differentially diagnose patients with C3G using evidence-based tools and strategies, Identify the mechanisms of action for agents targeted at specific complement inhibitors (eg, Factors B, C5a, C3, etc), Incorporate the latest findings for approved and emerging pharmacotherapies to optimize the management of patients with C3G.

Go online to PeerView.com/JUQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) has historically been associated with significantly poor outcomes, but recent advances with immunotherapies and targeted agents have improved outcomes in advanced TNBC, and they are now transitioning to early-stage settings as well. In this PeerView MasterClass and Practicum educational video, recorded at the SSO 2022 International Conference on Surgical Cancer Care, two experts in breast medical oncology and surgery discuss key clinical and surgical challenges associated with treating TNBC. In addition, they discuss available treatment options, such as immune checkpoint inhibitors (ICIs), poly ADP-ribose polymerase (PARP) inhibitors, and other emerging systemic agents being used as components of multimodal management strategies for TNBC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale,

Go online to PeerView.com/DRJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to bring modern approaches to the treatment of patients with biliary cancers to your clinical practice? Learn how the treatment paradigm is shifting from conventional chemotherapy to biomarker-guided treatments and immunotherapy in a new event from PeerView and the Cholangiocarcinoma Foundation. Our experts will offer learners a deep dive into the latest science on the biologic rationale for targeting prevalent genetic aberrations in biliary cancers and review key safety and efficacy data from recent pivotal clinical trials of novel strategies. Through discussions of relevant patient scenarios, our panel will offer insight on how to integrate biomarker-guided treatments into clinical practice and practical guidance on identifying patients with advanced biliary cancers who are eligible for targeted treatment. Upon completion of this CE activity, participants will

Go online to PeerView.com/GAS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management. Upon completion of this CE activity, participants will be able to: Discuss current challenges, unmet needs, and newer developments in ITP including the importance of differential diagnosis, testing, and guideline recommendations in treatment decision-making, Analyze safety, efficacy, evidence, and mechanism of action of BTKis and other emerging agents to improve quality of life and invoke long-term, off-treatment remissions, Develop personalized treatment plans for front-line and second-line therapies based on patient- and disease-specific factors to improve patient outcomes